Brinzolamide IP / USP

Product Name : Brinzolamide

CAS : 138890-62-7

Molecular Formula : C12H21N3O5S3

Molecular Weight : 383.5 g/mol

Pharmaceutical Grade : IP / USP

Therapeutic Category : Ophthalmic (ocular hypertension)


Global Calcium is one of the leading manufacturers and exporters of Brinzolamide CAS no. 138890-62-7, API, (Active Pharmaceutical Ingredient). We support the customers with exhaustive documentation. As a USDMF & EU-GMP certified global company and an established hallmark for pharmaceutical standards, Global Calcium has stood the test of time since its inception in 1979.

As manufacturer of Brinzolamide we hereby state the following facts about the drug:

Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase inhibitor. Carbonic anhydrase is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II. Following topical ocular administration, brinzolamide inhibits carbonic anhydrase II, an enzyme that is responsible for the movement of sodium and fluid transport in the eye. This inhibition leads to a decrease in aqueous humor secretion, probably by slowing the formation of bicarbonate ions and results in a reduction in intraocular pressure.

Brinzolamide is absorbed systemically following topical ocular administration. Since it has a high affinity for carbonic anhydrase II, brinzolamide binds extensively to red blood cells, where carbonic anhydrase II is primarily found. As sufficient carbonic anhydrase II activity remains, adverse effects resulting from the systemic inhibition of CA by brinzolamide are not observed.


Therapeutic uses and effectiveness:

  • Brinzolamide is used for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma
  • It was found useful to decrease elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient intraocular pressure reduction
  • Brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. It can decrease intraocular pressure by approximately 16-19% in patients with elevated intraocular pressure
  • In a randomized, double-masked, controlled study the intraocular pressure-lowering effect was evaluated using travoprost and brinzolamide within the first 24 h after phacoemulsification cataract surgery. The study concluded that both travoprost and brinzolamide significantly lowered intraocular pressure after small incision phacoemulsification cataract surgery within the first 24 h without any side effect
  • In another  study, the effect of topical brinzolamide on retinal capillary blood flow by in patients with glaucoma was checked and it was found that topical brinzolamide reduced the intraocular pressure significantly and apparently improved retinal blood flow

Other related information:

  • In clinical studies of brinzolamide ophthalmic suspension 1%, the most frequently reported adverse reactions reported in 5 to 10% of patients were blurred vision and bitter, sour or unusual taste. Adverse reactions occurring in 1 to 5% of patients were blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia, ocular discharge, ocular discomfort, ocular keratitis, ocular pain, ocular pruritus, and rhinitis

Global Calcium is a leading manufacturer of this drug. We manufacture this pharmaceutical drug and make it available to domestic and overseas market